By Josh White
Date: Thursday 09 May 2024
(Sharecast News) - Life science investor Syncona reported positive findings from its portfolio company Freeline Therapeutics on Thursday, after a phase one and two study of its gene therapy candidate for Gaucher disease, 'FLT20', showed encouraging results.
By Iain Gilbert
Date: Thursday 08 Feb 2024
(Sharecast News) - Life sciences investor Syncona said on Thursday that its net asset value had grown in the three months ended 31 December, driven by a prioritisation of capital allocation across its portfolio to enable the delivery of key inflection points.
By Josh White
Date: Thursday 16 Nov 2023
(Sharecast News) - Life science specialist Syncona reported a net asset value of £1.2bn at the end of its first half on Thursday, down from £1.25bn on 31 March, with a net asset value return of -4.2% during the period.
Currency | UK Pounds |
Share Price | 110.60p |
Change Today | -0.40p |
% Change | -0.36 % |
52 Week High | 159.00 |
52 Week Low | 106.20 |
Volume | 704,858 |
Shares Issued | 649.35m |
Market Cap | £718.18m |
RiskGrade | 291 |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
Strong Buy | 2 |
Buy | 1 |
Neutral | 1 |
Sell | 0 |
Strong Sell | 0 |
Total | 4 |
Latest | Previous | |
---|---|---|
Final | Final | |
Ex-Div | 21-Jun-18 | 20-Jul-17 |
Paid | 30-Jul-18 | 23-Aug-17 |
Amount | 2.30p | 2.30p |
Time | Volume / Share Price |
16:39 | 54,000 @ 110.60p |
16:39 | 54,000 @ 110.60p |
16:38 | 65,000 @ 110.60p |
16:16 | 987 @ 111.00p |
16:11 | 1,468 @ 110.40p |
You are here: research